India's National Pharmaceutical Pricing Authority is busy on both the pharma and device fronts to bring down costs to consumers. But the efforts may do more harm than good, according to an industry-sponsored study by IMS Health in India.
Foundation Medicine and IMS Health have teamed up to offer a precision medicine service. The alliance brings together Foundation Medicine's cancer genomics database and IMS' real-world evidence platform, a combination the partners think can enable the effective use of more targeted therapies.
Foundation Medicine is teaming up with healthcare technology firm IMS Health to develop a new cancer diagnostics tool, deepening the company's dive into cancer R&D a few months after it finalized its $1.2 billion deal with Roche.
Cancer drug pricing is turning more and more heads, especially as critical payers threaten a crackdown in the oncology field. And there's a reason for all the hullabaloo: Spending on oncology meds is increasing rapidly, new IMS numbers show.
When surveyed about their outlook, pharma industry leaders said they felt plagued by uncertainty and beaten down by budget cuts. More than half worried they would receive pink slips by the end of this year. But some more optimistic execs predicted new investment in their departments, and many figured staffing levels will endure, at least for this year.
Over the past two years IMS Health has counted 22 new cancer drugs on the market, a hefty portion of all new drug launches over that period. And by their calculations, the boom is just beginning.
The IPO was priced at $20 a share--above the midpoint of the range--and rose when trading began on Friday.
While the red-hot biotech initial public offering (IPO) market has grabbed headlines over the past year, tech companies that service these businesses have also cashed in. IMS Health signaled its intent to hop aboard the bandwagon at the start of the year, and it is now reportedly weeks away from going public.
The worst of the patent cliff has now passed, but IMS Institute for Healthcare Informatics has some bad news for the top 17 pharma companies: You still need to slash $36 billion from annual operating costs.
Inherent conservatism and a lack of regulatory guidance have caused pharma to edge slowly onto social media platforms. Yet patients still talk about their health online. Should drugmakers be listening?